We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
- Authors
Cai, Ping; Liu, Suhui; Duan, Lijuan; Huo, Li; Wu, Depei; Chen, Suning; Yang, Ruyu; Yang, Xiaofei
- Abstract
The translocation t(8;9) produces the fusion gene PCM1-JAK2, resulting in the continuous activation of the JAK2 tyrosine kinase. Myelodysplastic/myeloproliferative neoplasms are the most common disease with t(8;9)/PCM1-JAK2. Individuals with this abnormality have similar features, and JAK2 kinase inhibitor (ruxolitinib) is an effective treatment of the condition. The long-term remission results of ruxolitinib are varied. It is important to determine the response to ruxolitinib. Here, we describe a patient who has been diagnosed with eosinophilia-associated myeloproliferative neoplasm with t(8;9)(p21;p24). This patient has achieved sustained response for >1 year since the administration of ruxolitinib.
- Subjects
MYELOPROLIFERATIVE neoplasms; RUXOLITINIB; KINASE inhibitors; PROTEIN-tyrosine kinases; GENE fusion; MYELOFIBROSIS
- Publication
Acta Haematologica, 2023, Vol 146, Issue 5, p397
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000510281